Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Tucatinib in Combination with Palbociclib and Letrozole|DRUG: Tucatinib in Combination with Palbociclib and Letrozole
Sponsor: University of Colorado, Denver
Collaborators: Pfizer|Cascadian Therapeutics Inc.|Criterium, Inc.